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various reasons, as directly and straightforwardly outlined in the
discussion of the article. Nevertheless, we are somewhat aston-
ished by the reason for the critical comments by Drs Huland and
Heinzer, related for the most part to the fact that they only rely
their discussion on non-randomized studies including selected
population of patients. In fact, we lack references to well
controlled studies. An obvious shortcoming of most of the previ-
ously published studies within the field of immunotherapy is the
conclusion that the response rate was superior to ‘historic
controls’, although these trials were not randomized, and did not
use case-matched controls (Philip et al, 1993).
It has to be emphasized that our study investigated the general
applicability of the therapy concept in the management of patients
with good performance status (WHO 0–2). Even if it is a possibility
that the doses delivered to the patients are lower than proposed to
be optimal by Huland and Heinzer, it was clear that in our hands
many of the patients (note patients with high performance status)
required dose-reduction to be able to manage the treatment at all.
The toxicity encountered was in accordance with earlier reported,
and included a substantial number of patients with grade 3 and 4
toxicity. Thus, the adverse effects seen deteriorated quality of life in
a significant manner of the patients treated with immunotherapy.
Publication is also underway for the final evaluation of quality of
life for the whole study. This gives at least a further support that the
doses used were of clinical significance, i.e. the toxicity was
substantial. There exist no conclusive studies that clearly demon-
strate a dose–response relationship for cytokines in the clinical situ-
ation. Most likely, there is a quite different dose–response
correlation for cytokines (‘bell-shaped’) compared to chemothera-
peutics. Thus, it is not clear that ‘more is better’.
The survival in our study was similar in the two groups of
patients, even in respect to long-term survival. Moreover, the
survival was quite comparable with survival data reported in other
studies of renal cell carcinoma patients treated with IL-2/a-IFN
(e.g. Facendola et al, 1995). In fact, median survival in each of the
treatment arms was better than that seen in Swedish registry
studies. This gives further support that the doses delivered to
patients were of clinical significance. The survival analysis did not
seem to be different regardless of the time frame of the analysis
(from the date of primary diagnosis or the start of the treatment or
from the time of first signs of metastatic spread).
There was no obvious initial variation in laboratory parameters
or metastatic spread of the disease, which further reduces the risk
of differences in prognostic factors between the groups.
Furthermore, there exist several previously published studies that
support our observations (Steineck et al, 1990; Wagstaff et al,
1995; Ljungberg and Henriksson, 1997).
The past decades have without doubt shown an outstanding
increase in the knowledge about tumour immunology and
biotherapy. In renal cell carcinoma, the relatively high response
figures induced by a biotherapy approach have encouraged exten-
sive clinical studies. We would like to stress that we do not deny
the beneficial effects of biotherapy seen by several other authors
(e.g. Atzpodien et al, 1995), and agree that there might exist
subgroup of highly selected patients with renal cell carcinoma that
can really benefit from biotherapy. We also agree that other treat-
ment approaches, like inhalation of IL-2, can be promising.
Therefore, we are eagerly waiting the first reported experiences
from 1989 of local delivery of IL-2 by Huland and co-workers
evaluated in a controlled randomized study.
At present, regardless of our study, there is no standard
immunotherapy (a conclusion made in our study) that can be
recommended since the results obtained do not suggest an obvious
therapeutic benefit for the larger patient population suffering from
advanced renal cell carcinoma. It is obvious that there is much
need for investigation to find the optimal biotherapy schedule, i.e.
a significant increase in survival with an acceptable quality of life.
R Henriksson
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Hereditary factors in basal cell carcinoma of the skin: a
population-based cohort study in twins
Sir,
Milan et al (Br J Cancer 1998 78: 1516–1520) reported on a large
twin study investigating the contribution of hereditary factors in
basal cell carcinoma (BCC) in Finland. This twin study based on
12 941 adult twin pairs with 43 years follow-up data concluded
that genetic factors are not necessary to explain the distribution of
BCC in twins. These findings are of major importance; however, a
number of points need to be addressed in the analysis before these
conclusions can be accepted.248 Letters to the Editor
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1. The first limit to inference is the power of the study, which is
insufficient to rule out a genetic effect. Although the CE model
was reported as fitting the data best, the confidence intervals
for A (additive genetic effects) in the AE and ACE models are
very large. Both confidence intervals for A and C (shared
environment) contains 0 for the ACE model. A genetic effect
as large as 60% cannot be ruled out by this study. Accepting C
in place of A for discontinuous traits is logistically difficult
and would require a sample size of at least 20 000 twin pairs
given the prevalence of basal cell carcinomas of around 2%
(Neale et al, 1994).
2. The authors do not explore or comment on the significant
common environmental influence that has been observed,
which could merely be due to the age-dependence of BCCs.
The mean age of onset for sporadic BCC is around 65 years of
age, whilst familial tumours usually occur at younger age and
are often multiple (Kimonis et al, 1997). Failure to account for
age may mask the importance of a heritable component in the
data.
3. No account was taken of body sites. In genetically susceptible
families, it is well recognized that tumours are more often
found on the trunk than the face (Kimonis et al, 1997). By
combining all body sites in the analysis, it may have masked a
site-specific genetic effect.
4. Loss of heterozygosity studies have shown that 60% of BCCs
show loss of chromosome 9q, which harbour the patched
(PTC) gene (Gailani et al, 1992). Germline mutations in the
PTC gene are found in patients with naevoid BCC syndrome, a
family cancer syndrome characterized by multiple early onset
BCCs and developmental defects (Johnson et al, 1991). A
genetic basis for this disease is therefore likely and can only be
adequately discounted in much larger studies using designs
that take into account the known biological properties of the
disease.
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Hereditary factors in basal cell carcinoma of the skin:
a population-based cohort study in twins￿reply
Sir,
We thank Dr Bataille and her colleagues for their interest in our
paper on hereditary factors in basal cell carcinoma of the skin
(BCC), based on large population-based sample of adult twins
from Finland (Milan et al, 1998). They write that we concluded
that genetic factors are not necessary to explain the distribution of
BCC in twins, and raise a number of issues that they believe we
should have addressed.
It should first be pointed out that our conclusion was (as stated
in the last sentence of the abstract) that the results confirm the
major role of environmental factors, which was based on our
results from various genetic models shown in Table 4. In the
Introduction, we state that genetic disorders are known to be asso-
ciated with the development of BCC; in the Discussion, we
suggest that these disorders do not appear to be of major impor-
tance at the population level.
The decision to emphasise the best-fitting model, CE, with
shared (C) and unshared (E) environmental effects, derives from
the logic of model-fitting, which is to seek a model which accounts
for the observed data in the most parsimonious fashion, as advo-
cated by the standard text on twin analyses (Neale and Cardon,
1992). Such a model is more easily falsifiable in a subsequent
study than a more complex model, and we look forward to other
analyses of BCC from large, population-based twin or family data
sets. The more complex ACE-model did indeed contain the point
estimate of zero for both additive genetic effects (A) and shared
environmental effects (C), but the pure environmental model, E-
model, could be rejected. Nonetheless, in the ACE model, the
point estimate for the additive genetic component was 7.7%,
leaving over 90% of the inter-individual variability in the liability
to BCC to be attributed to environmental effects. The remaining
AE model, which Dr Bataille appears to be advocating, had a
poorer fit than the CE or ACE models.
Precisely because of the power issue (only four MZ and seven
DZ concordant pairs), we could not account for age effects in
genetic modelling. It certainly would be desirable to have more
twin pairs for such an analysis, but most twin study samples in the
world are considerably smaller than ours.
The mean age of diagnosis of the twins in the concordant pairs
was 64.1 years (range 38–82 years, both extremes being MZ male
twins, four out of 22 twins being diagnosed prior to age 60 years).
The twins from concordant pairs were not markedly younger than
were the other BCC patients on average. Failure to account for age
in genetic modelling thus appears to be an unlikely explanation for
not observing genetic effects.
Three-quarters (73%) of all BCCs registered with the Finnish
Cancer Registry between 1953 and 1995 were located in the head
and neck (unpublished data), compared with 68% of the twins
from the concordant pairs of the present study. One MZ pair (ages
at diagnosis 38 years and 43 years) and one DZ pair (60 and 61
years) were concordant for having a trunk location.
The identification of the role of the patched gene in the patho-
genesis of BCC is a very important observation, which we also
indicated (with three references) in our Discussion. However, the
basal cell naevus syndrome is a rare disease, and accounts for only
a very minor fraction of all BCCs in the population. The role of
germline mutations in the patched gene in sporadic BCC cases
should be assessed by the careful study of an unselected BCC